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How to read this report 
This report commences with a brief summary which focuses on gaps in the evidence base 
and implications for future research. This is followed by a brief background chapter (one) 
and the aims and methods in chapter two. The findings chapter (three) starts with an 
overview of the results from the search and a descriptive overview of all the papers 
included in the map. The findings are then presented, in turn, for each sub-set of papers 
determined by the topic focus (e.g., diagnosis, symptoms and co-occurring conditions, 
treatment, etc.). In chapter five, a discussion of the map’s overall findings and its 
conclusions are presented. This is followed by a detailed methods chapter (five), which 
presents the handling of the reports identified, screened, and otherwise examined, during 
the mapping process. An example search strategy is provided in the appendix. A catalogue 
of the included papers by sub-set is provided in supplementary files. 
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Executive Summary 
Background  
Lyme disease is the result of an infection, caused by the Borrelia burgdorferi bacterium, 
which is common in ticks; people can develop Lyme disease after being bitten by an 
infected tick. This report is part of a series of evidence reviews on Lyme disease 
commissioned by the Department of Health (England) Policy Research Programme and 
undertaken by the Department of Health Reviews Facility. This report contains a 
systematic evidence map; it provides a descriptive overview of the available research on 
Lyme disease in humans. 
Review questions and methods 
The systematic map aimed to address the following question: 
 What is the nature and extent of empirical research evidence on Lyme disease in 
humans? 
We searched 17 electronic databases and conducted additional web-based searching for 
unpublished and grey literature. Papers were included in the map if they reported 
empirical research, published in or since 2002, on Lyme disease in humans. All papers 
were coded in relation to their topic focus and key characteristics. Papers were 
categorised into one of nine groups; seven groups reflect the aspect of Lyme that the 
paper primarily focused on: i.e. diagnosis; symptoms and co-occurring conditions; 
incidence and prevalence; prevention; treatment; risk factors; and costs. The remaining 
two groups cover systematic reviews and papers which focus on more than one of the 
above categories, for example, papers focusing on both diagnosis and treatment. In 
addition to mapping the research literature, we also undertook a brief scan of the most 
popular websites to understand the sources of information that are available to the public 
through online searches. 
Findings 
A large, diverse and growing body of literature on Lyme disease was identified. In total, 
1,098 papers were included, with publications in the field of Lyme disease increasing 
steadily since 2002. The majority of papers were from Europe (n=631); approximately five 
percent (n=47) were from the UK. There was a particularly predominant evidence base 
from the USA (n=404 papers). 
Almost three quarters of papers focused on just three aspects of Lyme disease; diagnosis 
(n=310), symptoms and co-occurring conditions (n=283), and incidence and prevalence of 
Lyme disease (n=189). Far fewer papers focused on Lyme disease prevention (n=82), 
treatment (n=78), risk factors (n=46), or costs (n=10). Eighty-one papers focused on more 
than one of the above aspects of Lyme disease, and 19 were systematic reviews. 
Most of the diagnosis papers focused on the accuracy of diagnostic tests (n=253). Of the 
remainder, 19 focused on patient experiences of diagnosis, 18 focused on clinician 
knowledge and behaviours in relation to diagnosis, and 21 focused on other diagnosis-
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related issues. One paper reported both clinician views and the accuracy of diagnostic 
tests. 
Papers on symptoms, co-infections and co-occurring conditions (n=283), focused either on 
symptoms or manifestations of Lyme, such as Lyme neuroborreliosis or Lyme arthritis 
(n=73), on the association between Lyme disease and other tick-borne infections (n=41), 
or on the association between Lyme disease and other conditions, such as Parkinson’s 
disease (n=156). A small number focused on other symptom-related issues (n=13). 
The incidence and prevalence papers (n=189) predominantly focused on incidence (i.e. 
new cases of Lyme disease in a population) (n=126), with fewer measuring prevalence (i.e. 
the total number of cases within a population) (n=60). A very small number of papers 
focused on both incidence and prevalence (n=3). 
Papers on the prevention of Lyme disease (n=82) focused either on people’s knowledge 
and behaviour (n=42) or on the effectiveness or cost-effectiveness of interventions to 
prevent Lyme disease (n=40). 
Approximately one third of treatment papers examined the safety or effectiveness of one 
specific type of antibiotic (n=24) or other specific treatment (n=2). Other papers examined 
multiple antibiotic treatments (n=23), either used together as combination therapies, or 
to compare the effectiveness of one treatment versus another. The remainder (n=29), 
focused on specific patients, rather than specific treatments; that is, they examined 
whether symptoms had resolved in a cohort of patients who received antibiotic treatment 
of any kind. 
Papers on risk factors (n=46) examined whether the risk of Lyme disease infection was 
affected by season/climate (n=10), landscape factors (n=6), residential location (n=4), 
contact with animals (n=3), or other factors (n=3). Four papers examined the risk of 
human-to-human transmission (n=4). Sixteen papers examined more than one of the above 
risk factors. 
Of the few cost assessments identified (n=10), the majority (n=7) provided information on 
costs or resource use relating to the diagnosis and treatment of Lyme disease; the 
remainder (n=3) evaluated the relative costs and outcomes of different diagnostic and/or 
treatment approaches. 
Of the papers that explicitly aimed to examine more than one of the above aspects of 
Lyme disease (n=81), almost half focused on both symptoms and treatment (n=35). Other 
common combinations included incidence and prevalence and risk factors (n=12), 
diagnosis, symptoms and treatment (n=7) or symptoms, treatment and incidence and 
prevalence (n=7). 
We identified 19 systematic reviews; these focused on diagnosis (n=4), symptoms and co-
occurring conditions (n=2), incidence and prevalence (n=1), prevention (n=4), treatment 
(n=6), and risk factors (n=1). 
In the media scan, we found that the majority of webpages (n=9), on the first page of a 
Google search, gave factual information about the condition, with NHS Choices being the 
most consulted page. 
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As part of the broader project on Lyme disease, studies were identified from within this 
map to populate four in-depth systematic reviews. These reviews focus on: 1) the 
incidence and surveillance of Lyme disease (Lorenc et al. 2017); 2) experiences of Lyme 
disease diagnosis (Brunton et al. 2017); 3) experiences of treatment for Lyme disease 
(Sutcliffe et al. 2017a); and 4) prevention of Lyme disease (Richardson et al. 2017). 
Conclusions 
There is little research that focuses on specific vulnerable populations other than 
children, for example, older people and pregnant women. There is limited research into 
the diagnosis of Lyme disease via signs and symptoms, as opposed to via laboratory tests.  
There are relatively few papers on treatment and prevention; in particular, more 
controlled-design studies might prove beneficial for these topics. There is limited research 
on the risk factors and the costs associated with Lyme disease. Research into Lyme disease 
might also benefit from papers that focus on more clearly defined populations, 
interventions or outcomes, and are clearly reported. 
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1 Background 
This report is part of a series of reports on Lyme disease, commissioned by the 
Department of Health (England) (DH) Policy Research Programme and undertaken by the 
Department of Health Reviews Facility. 
The overarching project consists of a comprehensive evidence map on Lyme disease in 
humans and four systematic reviews on: 
1) the incidence and surveillance of Lyme disease 
2) patient, clinician and researcher experiences of the diagnosis of Lyme disease 
3) patient, clinician and researcher experiences of treatment for Lyme disease 
4) prevention of Lyme disease 
This report contains the findings from the systematic evidence map. 
The objective of this map is to provide a comprehensive overview of available research 
evidence relating to Lyme disease in humans. Our aim was to produce a descriptive 
account of the key characteristics of papers and identify any gaps in the research evidence 
base. 
1.1 Lyme disease 
Lyme disease is the result of an infection, caused by the Borrelia burgdorferi1 bacterium, 
which is common in ticks; people can develop Lyme disease after being bitten by an 
infected tick (PHE 2015). 
In many cases, an early sign of the infection is an erythema-migrans or ‘bulls-eye’ rash 
(Stanek and Strle, 2003, Wormser et al., 2006). Clinical complications resulting from Lyme 
disease include joint, nervous system, and heart problems (Stanek et al., 2011, Stanek et 
al., 2012, Wormser et al., 2006). Some evidence suggests that presentation is not always 
typical (Bingham et al., 1995, Christen et al., 1993) and that complications may be more 
wide-ranging and persistent. However, uncertainties around persistent infection mean 
that the notion of chronic Lyme or post-treatment Lyme disease (PTLD) is contested  and 
has been the subject of ‘substantial and polarizing debate’ in the field of medicine for 
many years (Rebman et al., 2017). 
1.2 What is known about the evidence base relating to Lyme disease in humans? 
There exist a number of recent systematic reviews on Lyme disease that have focused on: 
the existence of chronic Lyme disease (Lantos and Wormser 2014; Lantos et al. 2015), the 
effectiveness of preventative efforts (Mowbray et al. 2012, Beaujean et al. 2016a and b), 
diagnostic test accuracy for Lyme disease (Leeflang et al. 2016) and on the treatment of 
Lyme disease (Dersch 2015a and b). The National Institute for Health and Care Excellence 
                                            
1 We refer here to ‘Borrelia burgdoferi sensu lato’ which includes all sub-species (including 
burgdorferi sensu stricto, afzelii, garinii, mayonii, bissettii, lusitaniae and spielmanii). We have 
used the abbreviated phrase in the text for improved accessibility. 
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(NICE) is also, presently, undertaking a series of evidence reviews which aim to inform the 
development of a clinical guideline on the diagnosis and management of Lyme disease. 
This work will include reviews of the evidence on the accuracy of diagnosis techniques and 
on the effectiveness of treatment. However, these systematic reviews each examine a 
single aspect of Lyme disease, to our knowledge, there have been no previous attempts to 
systematically identify and map the full range of existing literature on Lyme disease. 
1.3 The purpose and value of evidence mapping 
This report takes the form of a systematic evidence map (Gough et al. 2017). Systematic 
evidence maps describe and characterise research evidence, for example, in terms of the 
countries, research designs or populations focused on, or the methodologies used. Maps 
are distinct from systematic reviews as they do not involve assessment of research quality 
or synthesis of research findings, they are purely descriptive in nature. The benefits of 
systematic evidence maps lie in their ability to provide a broad overview of a particular 
research field, to identify gaps in the evidence base or help to prioritise the research 
questions that are appropriate for systematic review (Snilstveit et al. 2013; Sutcliffe et al. 
2017b). To enable readers to understand the landscape of research on a particular topic, 
maps should consist of a systematic search of a broad topic area, with the results 
presented in an easily navigable and user-friendly format (Miake-Lye et al. 2016). 
The purpose of this systematic evidence map, therefore, is to comprehensively describe 
the research field relating to Lyme disease in humans. The aim is to facilitate a greater 
understanding of what has been investigated and to identify areas which require further 
investigation. 
  
 6 
2 Aims and methods 
This section provides a brief overview of the methods used to conduct this systematic 
evidence map. A more detailed account of the methods is provided in Chapter 5. 
2.1 Aims 
The primary aim of the systematic evidence map is to describe the nature and range of 
available research evidence pertaining to Lyme disease in humans. To achieve this, this 
map describes the key characteristics of research papers and identifies gaps in the 
research evidence base. 
A secondary, or minor, aim of the project was to undertake a ‘media scan’ to identify the 
most popular websites relating to Lyme disease to understand the sources of information 
available to the public through online searches. 
 Review questions 
The evidence map aimed to address the following question: 
 What is the nature and extent of empirical research evidence on Lyme disease in 
humans? 
2.2 Methods 
 Study identification 
The systematic evidence map aimed to cover the breadth of research evidence on Lyme 
disease in humans. As such, a maximally sensitive search strategy was employed consisting 
of a single cluster of terms for Lyme disease. Details of the search strategy and databases 
used are provided in Chapter 5; an example search is shown in Appendix 1. 
 Inclusion criteria 
To be included in the map papers needed to: 
 Be published in or after 2002. 
 Be published in the English Language.  
 Be about Lyme disease. 
 Be an empirical research study OR systematic review. 
 Be about Lyme disease in humans. 
 Not focus purely on markers or mechanisms of Lyme disease within blood samples, 
tissue samples, or cells.   
Further detail on the rationale for these criteria is provided in section 5.2.2. 
 Data extraction and quality appraisal  
Reviewers extracted descriptive data from the included papers, using coding tools 
developed specifically for the map. The following information was extracted from all 
papers: 
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 Bibliographic details: e.g., publication details, date. 
 Geographical location: continent and individual country. 
 Population: e.g., children, adults, high-risk groups. 
 Aspect of Lyme: e.g., diagnosis, treatment, prevention. 
Coding tools, specific to each aspect of Lyme, focused on capturing more detailed 
information. Where relevant, this included research design (e.g., aim, research method); 
focus of investigation (e.g., type of diagnostic test, treatment or prevention programme); 
outcomes; and other contextual details. 
The figures reported denote individual publications, referred to as papers. There are 
potentially numerous linked papers, i.e. single studies reported in multiple papers or 
single papers that report on multiple studies. However, the large volume of included 
papers precluded the identification of all linked studies. 
 Quality assurance 
Papers for the map were initially screened independently by two reviewers at both the 
title and abstract and full-text screening stages, in order to identify potential differences 
in interpretation of the criteria and refine the guidance for reviewers. Screening was 
conducted by single reviewers, once an agreement rate of 90% was achieved. Papers were 
then coded by two reviewers, due to the complex nature of the identified papers, in order 
to ensure that the appropriate information was identified and extracted. To ensure 
consistency and accuracy in reporting, data cleaning steps were taken, such as checking 
that papers were not double coded, or coded and subsequently excluded. 
 Media Scan 
We carried out a simple search on the internet, on the 31st July, 2017, and investigated 
the first page of results, in order to assess the source and content of the most popular 
pages relating to Lyme disease.  
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3 Findings 
Summary of findings 
 1,098 research papers met the criteria for inclusion in the map. 
 Research interest in Lyme disease appears to have steadily increased since 2002. 
 Most of the research comes from Europe and North America. 
 The majority of papers focus on three aspects of Lyme disease: diagnosis; 
symptoms and co-occurring conditions; and incidence and prevalence. 
 Far fewer papers focus on Lyme disease treatment, prevention, risk factors or 
costs. 
 Some papers focus on more than one of the above aspects of Lyme disease and 
some report systematic reviews. 
The first section of this chapter (3.1) reports on the flow of literature through the review. 
The next section provides an overview of all of the included papers (3.2). The following 
sections provide additional detail on the papers that focus on specific aspects of Lyme 
disease, including: diagnosis (3.3), symptoms and co-occurring conditions (3.4), incidence 
and prevalence (3.5), prevention (3.6), treatment (3.7), risk factors (3.8), and costs (3.9).  
Further, we present information on the papers that investigated multiple aspects of Lyme 
disease (3.10) and systematic reviews that focused on Lyme disease (3.11). Due to the 
high number of papers included in this map, references are not included within the write-
up; instead a comprehensive table of papers is provided for each aspect of Lyme disease 
(see Appendices 4 to 12). 
3.1 Flow of literature through the review  
52,268 references were identified from the bibliographic database searches conducted in 
August 2016. Searching of other sources resulted in a further 5,206 references and patient 
advocacy groups provided us with 62 more. Of these, 29,541 were duplicates and 1,533 
were removed because of publication year (published before 19802) or type (notes, 
letters, editorials and book reviews). This resulted in 21,174 references being screened on 
title and abstract; 13,621 were excluded at this stage. Of the remaining 7,553 potential 
includes, we were able to obtain and re-screen 7,524 full-text papers. At this second stage 
of screening 6,440 reports were excluded, of which more than half were published before 
2002. This resulted in 1,098 papers that met all inclusion criteria (see Supplementary File 
1 for the references of included papers). A diagram illustrating the flow of literature 
through the review is provided in Appendix 2. 
 
                                            
2 This initial cut-off was used before 2002 was selected with the scientific advisory group; the 
initial rationale being that since the causal organism and transmission vector of Lyme disease was 
first identified in 1982, searching for papers published prior to that time would not be fruitful. 
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3.2 Overview of all included papers  
An overview of the 1,098 included papers and their key characteristics is provided below. 
We document the number of papers by year of publication, geographical location, 
population and aspect of Lyme disease focused on. 
 When were the papers published? 
The number of published papers on Lyme disease remained relatively stable between 2002 
and 2010, when it started to increase (Figure 3.2.1). The number for 2016 does not 
include figures for the latter part of August, and September to December, as database 
searches were completed in August 2016. The small number of papers from 2017 were 
provided by stakeholders during consultation, and are, therefore, not representative of 
the literature published in the whole year. 
Figure 3.2.1: Number of papers by year of publication (n=1,098) 
 
 Which countries were the papers from? 
More than half of papers originated from Europe (n=631), and over a third from North 
America (n=404) (see figure 3.2.2). This is consistent with the wide recognition of the 
presence of the disease in these two continents. Few papers focused on studies from other 
continents, including only one in Africa. Germany (n=80), Poland (n=58), Sweden (n=52) 
and the UK (n=46) were the European countries that accounted for the most papers on 
Lyme disease. In North America, most publications were from the USA (n=371). Some 
papers focused on more than one country or continent. The 19 systematic reviews (SR) 
included papers from multiple countries and were, therefore, grouped separately. 
Appendix 3 lists the number of publications by continent and country. 
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Figure 3.2.2: Number of papers by continent* (n=1,098) 
 
* Categories are not mutually exclusive 
 Which populations did the papers focus on? 
We coded the population focus of the papers as either a) groups with specific 
characteristics, including sociodemographic characteristics (age, ethnicity, or pregnant 
women), or people who carry out activities associated with an increased risk of Lyme 
disease (hiking, occupation, or pet owners) or clinicians; or b) as “nonspecific”, i.e. the 
paper does not focus on one of the above. As shown in Figure 3.2.3, the majority of papers 
reported on non-specific populations (n=876). This is followed by papers that focused on 
children (under 18 years old) (n=132) and those in high-risk occupations, such as forestry 
workers (n=54). Twenty-two papers focused on clinicians and only a handful focused on 
pregnant women (n=4) or ethnic groups, older people (>60 y. old) and pet owners (n=2 
each). 
Figure 3.2.3: Population focus of included papers* (n=1,098) 
 
* Categories are not mutually exclusive 
 Which aspect of Lyme disease did the papers focus on? 
We classified the included papers into one of nine mutually exclusive topic groups based 
on the aspect of Lyme disease that they focused on or if they were systematic reviews 
(Fig. 3.2.4). The most common aspects of Lyme disease studied were diagnosis (n=310), 
symptoms and co-occurring conditions (n=283) and incidence/prevalence (n=189). 
Substantially fewer papers focused on Lyme disease prevention (n=82), treatment for 
1
2
4
8
16
40
404
631
0 100 200 300 400 500 600 700
AFRICA
NO CONTINENT & COUNTRY REPORTED
AUSTRALASIA
SOUTH AMERICA
N/A SYSTEMATIC REVIEW
ASIA
NORTH AMERICA
EUROPE
2
2
2
4
10
22
54
132
876
0 100 200 300 400 500 600 700 800 900
PET OWNERS
OLDER PEOPLE (>60 Y. OLD)
ETHNIC GROUPS
PREGNANT WOMEN
HIKERS/OUTDOOR PURSUITS
CLINICIANS
HIGH-RISK OCCUPATION
CHILDREN (<18 Y. OLD)
NON-SPECIFIC POPULATION
 11 
Lyme disease (n=78), risk factors for Lyme disease (n=46) and economic factors (n=10). 
Further, we identified 19 systematic reviews and 81 papers which explicitly aimed to 
investigate more than one of the above Lyme disease topics. 
Figure 3.2.4: Aspect of Lyme disease (n=1,098) 
 
Figure 3.2.5, below, illustrates that for most aspects of Lyme disease, European papers 
accounted for the largest proportion, followed by papers from North America. However, 
among the papers on prevention and risk factors and costs, the largest proportion came 
from North America. 
Figure 3.2.5: Aspect of Lyme disease by continent* (n=1,079) 
 
*All papers except the 19 systematic reviews are included in this figure.  Data labels for 
continents with two papers or fewer are not displayed. 
Figure 3.2.6, below, illustrates the focus on different aspects of Lyme disease for each 
year; as noted above, the figures for 2016 and 2017 are incomplete. For most years the 
largest proportion of papers focused on diagnosis, but this was not the case for 2003, 
2006, 2011 or 2013 when there were more papers on symptoms and co-occurring 
conditions. The most recent year for which we have complete data (2015) is the first year 
in which papers on incidence and prevalence accounted for the largest proportion. 
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Figure 3.2.6: Aspect of Lyme disease by year* (n=1,098) 
  
These findings illustrate that the body of research on Lyme disease in humans, published 
since 2002, is large, diverse and growing. The following sections provide more detail on 
the nature of the papers focusing on each of the different aspects of Lyme disease.  
3.3 Papers on diagnosis of Lyme disease 
 Introduction 
This section describes the 310 papers that focused on the diagnosis of Lyme disease. A 
table, with details of each diagnosis paper, can be found in Supplementary File 2, 
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Diagnosis Symptoms Incidence and prevalence
Prevention Treatment Risk factors
Costs Multiple aspects Systematic Reviews
Nature of the evidence: Papers on the diagnosis of Lyme disease in humans. 
Extent of evidence: 310 papers. 
Research aims: The majority of papers assessed the accuracy of tests for diagnosing 
Lyme disease (n=253). The remainder explored patient views of diagnosis (n=19), 
clinician knowledge and/or behaviours relating to Lyme disease diagnosis (n=18), or 
other diagnosis-related issues (n=21). One paper focused on both test accuracy and 
clinician knowledge/behaviours. 
Diagnostic focus: The majority of papers focused on laboratory tests for diagnosing 
Lyme (n=234); a minority focused on symptom-based diagnosis (n=48) and nine 
investigated both. The diagnosis method was not coded for papers on patient views 
(n=19). 
Context of evidence: 197 papers originated from Europe, 15 of which were from the 
UK. Ninety-eight papers originated from North America. Two papers focused on both 
Europe and North America. There were 13 papers from other continents. 
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Appendix 4. A further 14 papers that focused on diagnosis, alongside other aspects of 
Lyme disease, are described in section 3.10 on papers with multiple foci. 
 What were the aims of the included papers? 
The majority of papers (n=253) explored diagnostic test accuracy (see figure 3.3.1). 
Among the remainder (n=57), 19 explored patient experiences of diagnosis, 18 focused on 
clinician knowledge and/or behaviours, and 21 looked at other aspects of diagnosis. These 
other papers focused on the misdiagnosis of Lyme disease (n=9), methods for reading and 
interpreting Western blot test results (n=4), the impact of sample preparation and storage 
on test outcomes (n=3), diagnosis among Lyme vaccine recipients (n=2), the challenges for 
laboratories in diagnosing Lyme disease (n=1), the usefulness of testing for Lyme among 
those with arthritis (n=1), and the association between positive tests and various Lyme 
disease symptoms (n=1). 
Laboratory diagnostic tests were the focus of 234 papers, the remaining papers focused on 
clinical diagnosis (n=48) or both clinical and laboratory diagnosis (n=9). The diagnosis 
method was not coded for papers on patient views (n=19). 
Figure 3.3.1: Diagnosis papers by research aims and diagnostic approach (n=310)* 
 
*One included paper had two foci. 
 What research designs were used? 
The papers on accuracy of diagnostic tests compared the tests they were studying with a 
reference standard, such as a clinician diagnosed erythema migrans rash or two-stage 
ELISA and Western-blot testing. Of the patient views papers, twelve were quantitative 
surveys and seven were qualitative interview studies. Of the clinician knowledge and 
behaviours papers, 16 were quantitative surveys, one was a qualitative interview study 
and one was a retrospective case review to assess clinician adherence to guidelines. A 
variety of methods were used in the papers on other diagnostic issues. 
DIAGNOSIS TEST ACCURACY OTHER DIAGNOSIS ISSUES PRACTITIONER 
KNOWLEDGE/BEHAVIOURS
PATIENT EXPERIENCE OF 
DIAGNOSIS
Laboratory diagnosis Clinical diagnosis Both clinical and laboratory N/A patient views
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 Who were the research participants? 
Most of the papers (n=254) did not focus on a specific population. Of the remainder, 32 
focused on children, 18 on clinicians and six on those in high-risk occupations. 
 Where were the papers from? 
Table 3.3.1, below, shows the number of papers by continent. Within the 195 papers that 
were from Europe, 15 papers focused on the UK. Of these, seven explored patients’ views, 
four examined diagnostic test accuracy, one looked at clinician knowledge/behaviours and 
three examined other diagnosis issues. Other European papers most commonly came from 
Germany (n=31), Sweden (n=21), Finland (n=12), Poland (n=12) and Slovenia (n=12). 
Table 3.3.1: Diagnosis papers by continent (n=310) 
Continent Number of included papers* 
Europe 197 
North America 98 
Asia 11 
South America 1 
Australasia 1 
*Two papers focused on both Europe and North America  
3.4 Papers on symptoms and co-occurring conditions of Lyme disease 
 Introduction 
This section describes the 283 papers that examined Lyme disease symptoms or co-
occurring conditions. A comprehensive table of the included papers can be found in 
Supplementary File 2, Appendix 5. A further 61 papers that focused on symptoms, 
coinfections or co-occurring conditions, alongside other aspects of Lyme disease are 
described in section 3.10 on papers with multiple foci. 
Nature of the evidence: Papers that focused on symptoms and co-occurring 
conditions relating to Lyme disease in humans. 
Extent of evidence: 283 papers. 
Research aims: Seventy-three papers investigated the characteristics of Lyme 
disease symptoms or manifestations. The majority of papers examined associations 
between Lyme disease and other conditions (n=156). Forty-one investigated the 
association of Lyme disease with other tick-borne infections, and 13 examined 
other issues.  
Context of evidence: Most studies were from Europe (n=177) including 5 from the 
UK. Others were from North America (n=84), Asia (n=17), South America (n=4), and 
Australasia (n=1). Two studies did not report the continent/country. Two studies 
compared evidence from North America and Europe. 
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 What were the aims of the included papers? 
Seventy-three papers investigated the characteristics of well-established Lyme disease 
symptoms including Lyme neuroborreliosis (n=41), erythema migrans (n=13), Lyme arthritis 
(n=12), Lyme carditis (n=8) and acrodermatitis chronica atrophicans (n=2). One paper 
focused on several of the above symptoms. 
The majority of papers (n=156) examined whether Lyme disease is associated with other 
symptoms and conditions (i.e. not those listed above). The conditions examined included 
Parkinson’s disease, dementia, autism and many others. Of the 156 papers, 92 examined 
the presence of Lyme among populations with another condition, 60 examined the 
presence of other conditions among populations with Lyme, and four examined the 
correlation of Lyme with another condition. 
Forty-one papers investigated the association of Lyme disease with other tick-borne 
infections, such as Babesia or Anaplasmosis Rickettsia. Of these, 15 papers examined the 
presence of tick-borne infections among populations with Lyme, and 16 examined the 
presence of Lyme disease among those with other tick-borne infections. Seven examined 
the correlation between Lyme disease and other tick-born infections in ‘healthy’ 
populations – e.g., blood donors. Three papers examined the clinical characteristics of co-
infection. 
Lastly, 13 papers examined other issues, including the clinical features of early Lyme and 
the clinical features of those with different strains of infection. See Table 5 in the 
appendices for details. Figure 3.4.1, below, illustrates the number of papers focusing on 
each of the different research aims. 
Figure 3.4.1: Research aims of papers on symptoms and co-occurring conditions 
(n=283) 
 
N.B. Figures in pie sections denote numbers of papers and not percentages. 
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 What research designs were used? 
The majority of included papers reported that a single-group design was used (n=179); in 
the remainder (n=104) a controlled/comparative design was used.  
 Who were the research participants? 
Approximately one fifth of the papers focused on children (n=54). Older people, pregnant 
women and forestry workers were the focus of one paper each. The remainder (n=226) 
focused on non-specific or general adult populations. 
 Where were the papers from? 
The majority of papers were European (n=177), including five from the UK; European 
papers were most commonly from Germany (n=26), Poland (n=22), Czech Republic (n=16), 
Slovenia (n=16), Sweden (n=15), Austria (n=13) and Norway (n=10). Of the remainder, 84 
were from North America, 16 were from Asia, four were from South America, and one was 
from Australasia. Two papers did not report the continent/country. One paper compared 
evidence from North America and Europe. 
 Which outcomes were measured?  
The most common symptoms studied were neurological (brain) symptoms (n=89), followed 
by symptoms of the skin (n=44), joints (n=19), heart (n=17), eyes (n=13), immune system 
(n=4), ears (n=4), and urinary tract (n=2). Two papers examined functioning, three 
examined fatigue, one examined endocrinal symptoms and one examined flu-like 
symptoms. Sixteen papers examined other symptoms and 27 examined a range of 
symptoms. Forty-one focused on co-infections rather than symptoms. Some papers 
examined more than one symptom. 
3.5 Papers on incidence and prevalence of Lyme disease 
 Introduction 
This section describes 189 papers that investigated the incidence and prevalence of Lyme 
disease in humans. Incidence refers to the measurement of new cases of Lyme disease, 
while prevalence refers to the total number of existing or seroprevalent cases in the 
population at a given time. A comprehensive table of the included papers can be found in 
Supplementary File 2, Appendix 6. A further 31 papers that focused on incidence and 
Nature of the evidence: Papers that focused on the incidence or prevalence or 
Lyme disease in human populations. 
Extent of evidence: 189 papers. 
Research aims: Most papers examined Lyme disease incidence (n=126), fewer 
measured prevalence (n=60), and a very small number measured both (n=3). 
Context of evidence: More than half of publications (n=111) examined European 
populations. In Europe, the UK and Poland were the countries most studied. 
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prevalence, alongside other aspects of Lyme disease are described in section 3.10 on 
papers with multiple foci. 
 What were the aims of the included papers? 
Approximately two-thirds of papers focused on incidence (i.e. new cases of Lyme disease 
in a population) (n=126) with fewer measuring prevalence (i.e. the total number of cases 
within a population) (n=60). A small number of papers focused on both incidence and 
prevalence (n=3). 
Figure 3.5.1: Research aims of papers on the incidence and prevalence of Lyme 
disease (n=189) 
 
N.B. Figures in pie sections denote numbers of papers and not percentages. 
 
 What sources of data were used? 
Most commonly, papers analysed the existing data, including surveillance data (the figures 
collected by governmental authorities to track Lyme disease) (n=96), medical records 
(n=28), insurance claims (n=6), and laboratory data (n=6). The remaining papers used data 
collected as part of a research project (n=82); this includes research in general practices, 
and hospitals, as well as investigation of blood donors. We identified five further papers 
that used other sources, in one case the log book from a camp nursery, to estimate 
incidence and prevalence. In three papers, the data sources were unclear. Some papers 
used more than one data source. 
 How were the incidence and prevalence of Lyme disease measured? 
Most commonly, papers used a combination of laboratory and clinical assessment (n=72) to 
measure cases of Lyme disease. This is followed by the use of blood serum (n=55) or 
laboratory diagnosis alone (n=26). The use of clinical measures alone was less common, 
either via the International Classification of Disease (ICD) system (n=12) or via clinical 
manifestations (n=6). Patient self-reporting was used in a small number of papers (n=6). 
Many papers used more than one method. The measurement methods were unclear in 31 
papers. 
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 Who were the research participants? 
The majority of papers did not focus on a specific population (n=145). “High-risk 
occupation” is the group which was most examined (n=37). A few papers focused on 
children (n=4), people who did outdoor activities (n=2), and ethnic groups (n=1). 
Figure 3.5.2: Population focus of papers which examine the incidence and prevalence 
of Lyme disease (n=189) 
 
 
 Where were the papers from? 
More than half of papers focused on European populations (n=111), followed by North 
America (n=65). Table 3.4.1 below shows the number of included papers by continent. 
Seventeen papers described the incidence and prevalence of Lyme disease in UK 
populations, which, along with Poland (n=18), were the most evaluated countries in 
Europe, followed by Germany (n=12) and Italy (n=8). 
Table 3.4.1: Incidence and prevalence papers by continent (n=189) 
Continent Number of included papers 
Europe 111 
North America and the Caribbean 65 
Asia 8 
South America  3 
Africa 1 
Australasia 1 
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3.6 Papers on prevention of Lyme disease 
 Introduction 
This section describes the 82 papers on Lyme disease prevention. Two additional papers 
that focused on prevention alongside other aspects of Lyme disease are described in 
section 3.10 on papers with multiple foci. A comprehensive table of the included papers 
can be found in Supplementary File 2, Appendix 7. 
 What were the aims of the included papers? 
Of the 82 papers on Lyme disease prevention, just over half (n=42) were surveys 
measuring Lyme disease prevention knowledge and behaviours; the remainder (n=40) 
evaluated the effectiveness or cost-effectiveness of Lyme disease prevention 
interventions. 
Among the 42 knowledge and behaviour papers, 29 surveyed knowledge about Lyme 
disease prevention, 26 surveyed preventive behaviours, and six surveyed attitudes about 
Lyme prevention approaches or the communication of risks about Lyme disease. Twenty 
papers surveyed both knowledge and behaviours and one surveyed both Lyme knowledge 
and views on Lyme prevention interventions. 
 
 
 
 
 
Nature of the evidence: Papers that focus on Lyme disease prevention. 
Extent of evidence: 82 papers. 
Research aims: 42 papers examined people’s knowledge of and behaviours for 
preventing Lyme disease and 40 evaluated whether interventions to prevent Lyme 
disease are effective. 
Prevention focus: The knowledge and behaviour surveys (n=42) focused on one or 
more of: knowledge about Lyme prevention (n=29), preventive behaviours (n=26) or 
attitudes about prevention (n=6). The interventions evaluated (n=40) include: 
education (n=14), vaccines (n=10), personal protective measures (n=6), domestic 
protective measures (n=4), deer-targeted programmes (n=4), preventive antibiotics 
following a tick-bite (n=3) and habitat restoration (n=1). 
Context of evidence: 27 papers were from Europe of which 5 were from the UK. 
Fifty-eight papers were from North America. Four papers were from both Europe and 
North America. One paper was from Asia. 
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Figure 3.6.1: Research aims of papers on prevention knowledge and behaviour (n=42)* 
 
N.B. Figures in pie sections denote numbers of papers and not percentages. 
* papers may have multiple aims. 
Across the 40 papers on Lyme disease prevention interventions, a range of different 
interventions were examined, including: education (n=14), vaccines (n=10), personal 
protection measures, such as repellents or protective clothing (n=6), domestic protective 
measures, such as using chemical sprays in the garden (n=4), Lyme disease prophylaxis i.e. 
preventative antibiotic therapy following a tick bite (n=3), deer-targeted programmes 
(n=4), and habitat restoration (n=1). Two papers examined both personal protection and 
domestic protection measures. 
Figure 3.6.2: Research aims of papers on prevention interventions (n=40) 
 
N.B. Figures in pie sections denote numbers of papers and not percentages. 
* papers may have multiple aims. 
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 What research designs were used? 
Of the papers that examined knowledge and behaviours, 30 employed a quantitative 
survey design, six employed a qualitative design and six employed a mixed-methods 
design. Among the evaluations of Lyme prevention interventions, just over half employ a 
controlled/comparative design (n=21), of which nine were randomised controlled trials 
(RCTs), nine were controlled trials and three were case-control studies. Seventeen papers 
employed a single-group design; of these, nine employed a pre/post evaluation design, 
five conducted a retrospective review of medical records, two collected data following 
intervention implementation only and one was a case study. The remaining two papers 
provided a cost analysis; one examined the cost-effectiveness of a Lyme disease vaccine 
and the other estimated the cost-benefit of habitat restoration as a result of a reduction 
in Lyme-disease risk. See section 3.9 for further details. 
 Who were the research participants? 
Among the 42 papers examining knowledge and behaviours, most focused on the general 
public (n=31). The others focused on Lyme-prevention experts or professionals (n=6), both 
the public and Lyme professionals (n=4), and forestry workers (n=1). 
Among the 40 intervention papers, 30 interventions were delivered to non-specific 
populations, six were delivered to children, three to those working in high-risk 
occupations, and one to immigrants living in endemic areas of the United States. 
 Where were the papers from? 
This is one of only two categories of papers for which there were more North American 
papers (n=58) than European ones (n=27). Five papers were from the UK. Other European 
papers were from the Netherlands (n=8), Germany (n=4), Switzerland (n=4), Austria (n=2), 
Poland (n=2), and 1 from each from Czech Republic, Russia, Slovenia and Sweden. The 
North American papers were from USA (n=50) and Canada (n=8). One paper was from Asia 
(China). The total is greater than 82 as the data in four papers came from both Europe 
(Switzerland) and North America (Canada). Table 3.6.1 below provides a breakdown of the 
papers by research aim and continent. 
Table 3.6.1: Prevention papers by continent (n=82) 
Continent Knowledge and behaviour survey Evaluation of Lyme disease 
prevention interventions 
North America 28 30 
Europe 17 10 
Asia 1 0 
 
 Which outcomes were measured?  
Papers that examined knowledge and behaviours measured a range of outcomes. Those 
that focused on knowledge and awareness measured factors such as awareness of various 
risk factors and perception of risk, knowledge of Lyme symptoms and knowledge of 
prevention practices, such as tick removal. Papers that focused on prevention behaviours 
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measured factors such as wearing protective clothing, checking for ticks, and the use of 
insect repellents. 
Among the papers that evaluated the effectiveness of interventions, the outcomes 
measured include: increase in knowledge (n=15), efficacy and safety of clinical 
interventions (vaccine, prophylaxis) (n=12), incidence of Lyme infection (n=10), change in 
self-protective behaviour (n=7), acceptability of intervention (n=7), evidence of ticks/tick 
bites (n=4), and costs (n=1). Many papers focused on studies that employed multiple 
outcome measures. 
3.7 Papers on treatment for Lyme disease 
 Introduction 
This section describes the 78 papers which focused on the treatment of Lyme disease. A 
comprehensive table of the included papers can be found in Supplementary File 2, 
Appendix 8. A further 56 papers that focused on treatment alongside other aspects of 
Lyme disease are described in section 3.10 on papers with multiple foci. 
 What were the aims of the included papers? 
The majority of papers examined the effectiveness and/or safety of a single treatment 
(n=53), mainly a single antibiotic. Others compared the effectiveness of different 
treatments (n=14) or different lengths of treatment (n=8). Of the remainder, one paper 
compared different modes of delivery, one paper described antibiotic treatment patterns 
in over 10,000 patients with newly-diagnosed Lyme disease, and one paper explored 
beliefs about long-term antibiotic therapy among the general public. 
 
  
Nature of the evidence: Papers that focused on pharmacological or non-
pharmacological treatments for Lyme disease. 
Extent of evidence: 78 papers. 
Research aims: The majority of papers examined the effectiveness and safety of a 
single treatment for Lyme disease (n=53); others compared the effectiveness of 
different treatments (n=13) or different lengths of treatment (n=10). One paper 
described the nature of antibiotic treatments used in a large cohort of patients and 
one explored views about treatment for Lyme disease. 
Treatment focus: Most papers (n=76) focused on antibiotic drug interventions. Two 
studies focused on non-pharmacological treatments. 
Context of evidence: Most studies were conducted in European countries (n=43), of 
which only two were conducted in the UK. The remainder (n=35) were conducted in 
the USA. 
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Figure 3.7.1: Research aims of papers on the treatment of Lyme disease (n=78) 
 
N.B. Figures in pie sections denote numbers of papers and not percentages. 
 What types of treatment were studied? 
Most papers (n=76) focused on antibiotic therapy. Approximately one third of these papers 
examined the safety or effectiveness of one specific type of treatment only (n=26). Others 
examined multiple antibiotic treatments (n=23) either used together as combination 
therapies, or to compare the effectiveness of one treatment versus another. The 
remainder (n=29) did not focus on specific treatments, rather they focused on outcomes in 
a cohort of patients who had received a range of treatments. 
Of the two papers that did not focus on antibiotics, one examined the effects of exercise 
for patients with persistent symptoms and the other examined peripheral nerve 
stimulation for Lyme disease patients with intractable headaches. 
 What research designs were used? 
Half of the papers reported controlled or comparative design studies (n=39). Of these 14 
were RCTs, 13 were controlled trials, four were case-control studies and eight were 
comparative rather than controlled studies. The remaining papers (n=39) employed a 
single-group design. 
 Who were the research participants? 
Eight papers focused specifically on children and one on pregnant women; the remainder 
(n=69) did not have a specific population focus.  
Many papers focused on patients with specific Lyme disease symptoms, including Lyme 
neuroborreliosis (n=22), erythema migrans (n=17), cardiovascular involvement (n=4), Lyme 
arthritis (n=4), and facial palsy (n=3). Others focused on Lyme disease populations in 
general (n=20). One paper focused on treatment for Lyme patients co-infected with 
Babesia. The paper examining views about treatments collected evidence from the 
general public. 
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 Where were the papers from? 
The majority of papers were from Europe (n=43), of which only two were from the UK. 
Both UK papers were non-comparative studies that monitored the treatment effectiveness 
of antibiotics. The remaining papers were all North American (n=35). 
Table 3.7.1: Treatment papers by continent (n=78) 
Continent Number of included papers 
Europe 43 
North America 35 
 Which outcomes were measured? 
Of those papers assessing treatment effects (n=76), most measured changes in, or 
resolution of, physical symptoms (n=69). Some studies measured changes in biological 
markers, such as the presence of antibodies (n=36). Some focused on the adverse effects 
of treatment (n=20) and some on other outcomes, such as quality of life or cognitive 
function (n=6). Many papers measured more than one outcome. 
Over half of the papers focused on long-term outcomes, where patient outcomes were 
measured more than six months after receiving treatment (n=47); 19 papers measured 
short-term outcomes (i.e. outcomes were measured within six months of treatment). The 
remaining papers either did not specify when outcomes were measured (n=10) or the 
timing of outcome measurement was not relevant due to the type of paper (n=2). 
3.8 Papers on the risk factors for Lyme disease 
 Introduction 
We identified 46 papers which examined the association of Lyme disease with different 
potential risk factors. A comprehensive table of the included papers can be found in 
Supplementary File 2, Appendix 9. A further 15 papers that focused on risk factors 
alongside other aspects of Lyme disease are described in section 3.10 on papers with 
multiple foci. 
Nature of the evidence: Papers that focused on potential risk factors for Lyme 
disease. 
Extent of evidence: 46 papers. 
Research aims: The papers focused on a range of potential risk factors and their 
association with Lyme disease infection. Sixteen papers focused on multiple risk 
factors, and 30 focused on single risk factors, including season/climate (n=10), 
landscape factors (n=6), human-to-human transmission (n=4), residential location 
(n=4), contact with animals (n=3), or other factors (n=3). 
Context of evidence: No studies were conducted in the UK; 17 papers were from 
Europe and 29 from North America. 
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 What were the aims of the included papers? 
The papers examined whether the risk of Lyme disease infection is affected by a range of 
factors including season/climate (n=10), landscape factors (n=6), residential location (n=4) 
or contact with animals (n=3); sixteen papers examined more than one of the above risk 
factors. Four papers examined the risk of human-to-human transmission (n=4). One paper 
examined the risk of re-infection and one the level of risk following a tick-bite, in a highly 
endemic area of Switzerland. The remaining paper did not examine Lyme disease risk 
factors, but examined the influence of Lyme disease risk on the decision to settle in a 
high-prevalence area. 
Figure 3.8.1: Research aims of papers on risk factors of Lyme disease (n=46) 
 
N.B. Figures in pie sections denote numbers of papers and not percentages. 
 What research designs were used? 
The majority of papers employed an ecological design (n=33), for example, looking for 
correlations between Lyme disease incidence and geographical variation in the prevalence 
of risk factors, such as the climate or environment. Other designs include: survey (n=5), 
case series (n=3), case control (n=2), longitudinal serological survey (n=2), review of 
medical records (n=1), and risk behaviour simulation (n=1). One study employed both 
survey and serological testing. 
 Who were the research participants? 
Forty-one of the papers focused on a non-specific or general adult population. Of the 
remaining five papers, two focused on walkers/hikers, two focused on pregnant women 
and one focused on people in high-risk occupations. 
 Where were the papers from? 
None of the papers on risk factors were from the UK. Seventeen reported studies 
conducted in Europe; Czech Republic (n=5), Hungary (n=5), Belgium (n=2), Germany (n=2), 
France (n=1), Sweden (n=1) and Switzerland (n=1). Twenty-nine were from North America, 
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of which 28 were from the USA and one did not specify which North American country it 
was conducted in. 
 Which outcomes were measured? 
The papers on ecological studies, a simulation study and two of the case-series, estimated 
or hypothesised the association of risk factors with Lyme disease (n=34). The level of 
association between Lyme disease and risk factors was directly measured in ten papers, 
for example, via survey. The remaining two papers examined clinical evidence of human-
to-human transmission. 
3.9 Papers on the cost assessment of Lyme disease 
 
 Introduction 
This section focuses on cost assessments of various aspects of the management, 
treatment, impact, diagnosis, and other health care and health-related aspects of Lyme 
disease. Cost assessments are studies that examine either the cost-benefit, cost-
effectiveness, cost-utility, or cost savings of interventions or services. 
This section comprises ten papers that focused on cost assessments of services and 
impacts related to Lyme disease. An additional six papers were identified that briefly 
mention cost data within the context of a study that focused on another aspect of Lyme 
disease. These are summarised at the end of the section. A comprehensive table of the 
included papers can be found in Supplementary File 2, Appendix 10. 
Nature of the evidence: Papers that focused on economic or cost issues of 
healthcare relating to Lyme disease. 
Extent of evidence: 10 papers. 
Research aims: The majority of included papers focused on the costs of treating 
and caring for patients with Lyme disease (n=7); others focused on the costs of 
testing for Lyme disease (n=4). One paper focused on both therapeutic and 
diagnosis costs. 
Economic focus: All papers focused on health-related costs; they assessed the cost 
of laboratory testing, diagnosis, treatment and management. Four of these also 
assessed social costs, such as time and productivity lost due to Lyme disease (n=4). 
Context of evidence: Only one paper was from the UK. The majority of papers 
focused on the USA (n=6), followed by Germany (n=2) and Sweden (n=1). The 
majority of the papers focused on studies set in hospitals (n=4), with the remaining 
studies being set in unspecified clinics (n=1), other environments (n=3) or not 
explicit about where they were set (n=3). 
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 What were the aims of the included papers? 
The majority of included papers focused on the cost of service organisation and service 
delivery for Lyme disease (n=7), such as therapeutic costs and disease management, but 
also the costs to those impacted by Lyme disease, such as loss of time and productivity. 
Four papers focused on the cost of diagnosis or laboratory testing (n=4). One paper 
focused on both therapeutic and diagnosis costs. 
 What research designs were used? 
The majority of the included papers (n=7) reported cost and utilisation data, or cost-of-
illness information; these papers did not compare the cost and outcomes of alternative 
services or interventions. Two papers reported cost-effectiveness; that is they evaluated 
the effectiveness of an intervention, compared with alternative interventions, in terms of 
“cost per unit of effect”. One paper looked at length of stay in hospital for children with 
Lyme disease, comparing those who had laboratory tests with those who did not. 
 What setting was the focus for the papers? 
The papers focused on costs in hospital settings (n=4) or commercial laboratories (n=3). 
The setting in three papers was unclear. 
 Where were the papers from? 
The majority of papers were from the USA (n=6), with remainder being from Germany 
(n=2), the UK (n=1) and Sweden (n=1). The UK paper was from Scotland and provided a 
partial cost evaluation of a broad spectrum of health and social costs of Lyme disease. 
Table 3.9.1: Continent of focus for papers that describe cost assessments of Lyme 
disease in healthcare (n=10) 
Continent Number of included papers 
North America 6 
Europe 4 
 
 Which outcomes were measured? 
All papers focused on healthcare costs, i.e. the costs of clinical treatment, diagnosis, 
testing or consultation. However, four also looked at social costs, such as time and 
productivity lost due to Lyme disease. 
 Are there other papers that mention economic data? 
We located six further papers that provided brief sections on economic data within studies 
that primarily focused on another aspect of Lyme disease. The main focus of these papers 
was: prevention (n=2), prevalence (n=1), multiple aims (n=1), symptoms (n=1), or 
treatment (n=1). The economic perspective was varied; three papers provided partial 
evaluations, the others looked at cost-effectiveness (n=1), cost-benefit (n=1)) and 
resource utilisation data (n=1). All papers focused on health outcomes only. Further 
details about these papers can be found in the relevant sections. See Supplementary File 
7. 
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3.10 Papers on multiple aspects of Lyme disease 
 Introduction 
This section focuses on papers that had the explicit aim of investigating multiple clinical 
characteristics of Lyme disease; that is, they had a clear aim to examine two or more of a 
range of aspects of Lyme disease, within a single patient population. We identified 81 
papers for this category. A comprehensive table of the included papers can be found in 
Supplementary File 2, Appendix 11. 
 What were the aims of the included papers? 
The majority of papers (n=48) focused on the clinical characteristics or course of specific 
symptoms and co-occurring conditions associated with Lyme disease (n=28), and/or 
examined the clinical characteristics of Lyme disease within a specific population (n=21).  
Some papers had multiple clearly defined research aims (n=16), in that the authors were 
explicit that they would address two or more different aims in the paper. The remainder 
evaluated the clinical or microbiological findings of Lyme disease (n=6), investigated 
susceptibility to Lyme disease (n=5), evaluated clinician practices or adherence to 
recommendations (n=3), or defined the clinical characteristics of ongoing symptoms (n=2). 
The clinical aspects examined include symptoms (n=62), treatment (n=57), incidence and 
prevalence (n=31), risk factors (n=15), diagnosis (n=14), and prevention (n=2), with each 
paper examining more than one of these topics. 
 What research designs were used? 
The majority of included papers employed a single-group design (n=46), that is they did 
not employ a control or comparison group. There are a smaller number of papers that used 
controlled designs (n=15), none of which was a RCT. The remainder (n=23) employed 
various other designs: retrospective chart reviews (n=11), database analysis or surveillance 
Nature of the evidence: Papers that explicitly aimed to investigate multiple aspects 
of Lyme disease within a single patient population. 
Extent of evidence: 81 papers. 
Research aims: Most of the included papers (n=48) focused on the clinical 
characteristics, the course of specific symptoms and co-occurring conditions 
associated with Lyme disease (n=28), and/or examined the clinical characteristics of 
Lyme disease within a specific population (n=21). Papers mainly focused on Lyme 
disease in general (n=39), Lyme neuroborreliosis (n=11), erythema migrans (n=11) 
and/or Lyme arthritis (n=9). 
Research design: A variety of research designs was employed. Most papers used a 
single-group design (n=46), with a smaller number of papers using a controlled design 
(n=15), none of which was a RCT. 
Context of evidence: The majority of papers were from Europe (n=51). The country 
with the largest number of papers was the USA (n=25). 
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data (n=7), interviews or questionnaires (n=4), and one observational cohort study. Three 
papers employed more than one research design. 
 Who were the participants? 
Several papers focused on more than one population. Generally, papers focused on non-
specific populations (n=56). Those papers, in which the population was specified, mainly 
focused on children (n=19). There were also papers with a focus on a high-risk occupation 
(n=4), clinicians (n=2), hikers/outdoor pursuits (n=1) and older people (n=1). Papers 
mainly focused on post-treatment patients (n=49) or the general population (n=26). The 
remainder focused on patients currently undergoing treatment (n=5) and pre-treatment 
populations (n=4). Most commonly, papers focused on Lyme disease in general (n=39), in 
that they did not specify a particular manifestation. Some focused on Lyme 
neuroborreliosis (n=11), Lyme arthritis (n=11) and erythema migrans (n=11). The 
remainder focused on facial palsy (n=3), Post Lyme Disease Syndrome (PLDS) (n=3), Lyme 
carditis (n=2) and other systemic conditions: lymphocytoma in children (n=2), Lyme 
meningitis (n=1), and acute polyradiculoneuritis syndrome (n=1). Papers that focused on 
Lyme arthritis specifically focused on the child population. 
 Where were the papers from? 
The majority of papers were European (n=51); most commonly from Slovenia (n=8), Poland 
(n=6), Sweden (n=5), France (n=4), Norway (n=4), Germany (n=3) and Romania (n=3). The 
remaining thirteen European countries were the source for two or fewer papers per 
country; details can be found in Supplementary File 8. Only one UK paper was identified, 
which was a retrospective case note review study, focused on clinician practices in a 
referral clinic. North America accounted for 26 papers, and the remainder were from 
China (n=2), Turkey (n=1) and Australia (n=1). The country with the largest number of 
papers was the USA (n=25). Table 3.10.1 below details papers by continent.  
Table 3.10.1: Continent of focus for papers that examined multiple aspects of Lyme 
disease (n=81) 
Continent Number of included papers 
Europe 51 
North America 26 
Asia 3 
Australasia 1 
 
 Which outcomes were measured? 
The outcomes that were reported centred on the clinical characteristics being researched 
and included physical symptoms (n=61), biological characteristics (n=57) and non-
physiological measures (n=9). 
Physical symptoms that were reported were skin changes (n=32), neurological changes 
(n=25), clinician-identified symptoms (n=19), pain (n=14), inflammation (n=13), fever or 
flu-like symptoms (n=8), cardiac symptoms (n=7), and patient self-reported symptoms 
(n=6). 
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Biological characteristics that were reported mainly examined immunoblot for 
immunoglobulin M (IgM) and/or for immunioglobulin G (IgG) (n=29), blood serum (n=26), 
general antibodies (n=21) and polymerase chain reaction (PCR) positivity (n=9). The 
remainder were: cerebral spinal fluid (CSF) (n=7), magnetic resonance imaging (MRI) scan 
(n=2), biopsy results of particular cells or organs (n=2), and synovial fluid effusion (n=1). 
Non-physiological outcomes that were reported were incidence (n=6), prevalence (n=2) 
and service use (n=1). 
3.11 Systematic reviews on Lyme disease 
 
 Introduction 
Nineteen systematic reviews were identified.  One review was an update of a previous 
systematic review, and therefore, eighteen reviews were coded and analysed. The review-
level evidence base on Lyme disease in humans is relatively new, with over half published 
between 2015 and 2017 (n=11). The majority of reviews focused on treatment (n=5), 
prevention (n=4), and diagnosis (n=4) of Lyme disease, with fewer reviews on symptoms 
(n=2), incidence/prevalence (n=1), or risk factors (n=1). One review focused on chronic 
Lyme disease. A comprehensive table of the included papers can be found in 
Supplementary File 2, Appendix 12. 
 Systematic reviews on diagnosis (n=4) 
The diagnostic test accuracy (DTA) of serological assays (e.g., ELISA, or Western Blot) was 
investigated in four systematic reviews. Meta-analysis was undertaken in two reviews, one 
of which conducted a critical appraisal of studies from Europe. The scale of the evidence-
base varied from 75 to 12 studies. 
  
Nature of the evidence: Systematic reviews on Lyme disease in humans. 
Extent of evidence: 19 systematic reviews. 
Review aims: The reviews aimed to examine: treatment (n=5), prevention (n=4), 
diagnosis (n=4), symptoms (n=2), incidence and prevalence (n=1), risk factors (n=1) 
and chronic Lyme (n=1). 
Context of evidence: Two reviews included studies from Europe only. The 
remaining reviews did not apply a geographical filter. 
Gaps in research: There is a lack of systematic reviews on the prevalence of Lyme 
disease in the general population and the effectiveness of prevention interventions.   
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Table 3.11.1: Systematic reviews on diagnosis 
Authors Inclusion criteria Details of the review 
Population   Study focus     No. of 
studies  
Quality 
appraisal  
Type of 
synthesis  
Bakker et 
al. (2012) 
Adults  DTA: ELISA or Western 
blot, using cerebrospinal 
fluid  
n=12 Risk of 
bias 
Narrative 
synthesis   
Cook & Puri 
(2016) 
Adults DTA: PCR assay; ELISA, 
Western Blot 
n=18 None  
 
Meta-analysis 
Leeflang et 
al. (2016) 
Adults DTA: ELISA or an 
immunoblot assay 
n=75 Risk of 
bias 
Meta-analyses 
Stanek & 
Strle (2009) 
Adults  
Children 
DTA: Diagnostic assays or 
procedures 
Not 
reported 
None  
 
No synthesis 
DTA = diagnostic test accuracy; ELISA = enzyme-linked immunosorbent assay; PCR = 
polymerase chain reaction 
 Systematic reviews on symptoms and co-occurring conditions (n=2) 
Two systematic reviews considered the symptoms and manifestations of Lyme disease. 
One meta-analysis investigated the presence of residual symptoms in a cohort of adults 
after they had received pharmacological treatment for Lyme neuroborreliosis. A second 
review narratively explored the symptoms of Lyme disease in patients presenting with 
sudden deafness. 
Table 3.11.2: Systematic reviews on symptoms and co-occurring conditions  
 
Authors   
Inclusion criteria Details of the review 
Population Lyme diagnosis No. of 
included 
studies  
Quality 
appraisal  
Type of 
synthesis  
Dersch et 
al. (2016) 
Adults  Patients with Lyme 
neuroborreliosis after 
pharmacological 
treatment  
n=44 None Meta-analysis 
Peeters et 
al. (2013) 
Adults Patients presenting with 
sudden deafness 
n=9 None  
 
Narrative 
synthesis   
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Table 3.11.3: Systematic reviews on incidence and prevalence  
 
Authors   
Inclusion criteria Details of the review 
Population Lyme diagnosis No. of 
included 
studies  
Quality 
appraisal  
Type of 
Synthesis  
Sykes and 
Makiello 
(2016) 
Adults  
Children 
Confirmed cases of 
Lyme infection 
n=11 None  
 
Narrative 
synthesis   
 
 Systematic reviews on prevention (n=4) 
Three systematic reviews focused on the effectiveness of a single clinical treatment, such 
as vaccines (n=1) or antibiotics (n=1) in preventing Lyme disease, one of which conducted 
a meta-analysis. One systematic review focused solely on communication-based public 
health messages to encourage the use of protective behaviours. The scale of the evidence 
identified on prevention interventions is quite small, ranging from three to nine studies. 
The quality of the evidence base is unassessed. 
Table 3.11.4: Systematic reviews on prevention of Lyme disease 
 
Authors  
Inclusion criteria Details of the review 
Population Intervention type   No. of 
studies  
Quality 
appraisal  
Type of 
synthesis 
Badawi et 
al. (2017) 
Adults Vaccine n=7 None  
 
Narrative    
synthesis   
Mowbray and 
Rubin (2012) 
Adults 
Children 
Communications-based 
public health 
interventions 
n=9 None  
 
No 
synthesis 
Warshafsky 
et al. (2010) 
Adults 
Children 
Antibiotic prophylaxis n=4 None  
 
Meta-
analysis 
Zhao et al. 
(2017) 
Adults Vaccine  n=3 None  
 
Meta-
analysis 
 
 Systematic reviews on treatment (n=5) 
All five reviews on treatment investigated the effectiveness of antibiotics for treating 
Lyme disease. Four reviews included studies that focused on children or adults, where a 
clinical diagnosis of definite, possible or probable Lyme neuroborreliosis had been 
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established. One review focused specifically on children, and another on adults or children 
with any symptom of Lyme disease. A review, conducted to inform treatment guidelines, 
also included trials that investigated antibiotic therapy for patients who had received an 
initial course of antibiotics, but continued to experience symptoms associated with Lyme. 
The scale of the evidence base, identified in each review, ranged from six to 37 studies, 
with smaller reviews limiting their eligibility criteria to RCTs. Four reviews critically 
appraised trials using a risk of bias tool, two of which conducted a meta-analysis. 
Table 3.11.5: Systematic reviews on treatment  
 
Authors 
  
Inclusion criteria  Details of the review 
 
Population  Lyme 
diagnosis  
No. of 
studies  
Quality 
appraisal   
Type of 
synthesis 
Cadavid et al. 
2016) update of 
Cadavid (2008) 
Adults  
Children 
Clinical 
diagnosis  
n=7 Risk of 
bias 
Narrative 
synthesis   
Carris & Shaeer 
(2015) 
Adults  
Children 
Symptoms 
of Lyme 
disease 
n=6 Risk of 
bias 
 
Narrative 
synthesis   
Dersch et al. 
(2015a) 
Adults  
Children 
Clinical 
diagnosis 
n=16  Risk of 
bias 
 
Meta-analysis 
Dersch et al. 
(2015b) 
Children  Clinical 
diagnosis 
n=6 Risk of 
bias 
 
Meta-analysis 
Halperin et al. 
(2007) 
Adults  
Children 
Clinical 
diagnosis / 
post-Lyme 
symptoms  
n=37 None 
 
Narrative 
synthesis   
 
 Systematic reviews on incidence and prevalence of Lyme disease (n=1) 
One systematic review narratively reported on the incidence of Lyme disease in adults or 
children in Western Europe. 
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 Systematic reviews on risk factors (n=1) 
One review narratively synthesised evidence from geographic information system (GIS) 
studies. Studies contain data on spatiotemporal patterns and interactions between 
populations of reservoir hosts, clusters of infected ticks and humans to better understand 
the spread of Lyme disease transmission. Populations of interest included adults and 
children living in high-risk endemic areas or having high-risk occupations. 
Table 3.11.6: Systematic reviews on risk factors 
 
Authors 
Inclusion criteria  Details of the review  
 
Population   Study focus     No. of 
studies  
Quality 
appraisal  
Type of 
synthesis 
Ozdenerol et 
al. 2015 
Adults  
Children 
Spatiotemporal 
patterns of Lyme 
disease 
n=22 None  
 
Narrative 
synthesis   
 
 Systematic reviews on chronic Lyme disease (n=1) 
One review, provided a descriptive overview of 89 studies on the complexity of chronic 
Lyme disease. Complexity was understood in relation to the patients’ care needs, such as 
difficulty in diagnosing and treating Lyme disease when symptoms persist. 
Table 3.11.7: Systematic reviews on chronic Lyme disease  
 
Authors 
Inclusion criteria  Details of the review  
Population   Study focus     No. of 
studies  
Quality 
appraisal   
Type of 
synthesis 
Borgermans et 
al. 2014  
Adults  
Children 
Complexity of CLD as a 
multidimensional 
chronic disease 
construct 
n=89 None  
 
No 
synthesis 
CLD = chronic Lyme disease 
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3.12 Media scan on Lyme disease 
Our simple search to identify the sources of information about Lyme disease that are 
accessible to the general public, in the UK, resulted in identifying nine webpages on the 
first page of the Google search. The details of these nine sources can be found in table 
3.12 below. 
Table 3.12: results of media scan 
Name of Page Source Nature of 
source 
Link 
Lyme Disease  NHS choices Government https://www.nhs.uk/conditi
ons/lyme-disease/ 
FAQ Lyme 
Disease Action 
Lyme Disease 
Action 
Patient 
Group 
http://www.lymediseaseact
ion.org.uk/about-lyme/faq/ 
Home page - 
Lyme Disease 
Action 
Lyme Disease 
Action 
Patient 
Group 
http://www.lymediseaseact
ion.org.uk/ 
Lyme Disease Wikipedia Non 
commercial, 
factual 
https://en.wikipedia.org/wi
ki/Lyme_disease 
Lyme Disease 
(Borreliosis) 
BADA UK Patient 
Group  
Page no longer available 
Home page - 
Lyme Disease UK  
Lyme Disease 
UK 
Patient 
Group 
http://lymediseaseuk.com/
about-us/ 
Lyme Disease  NHS - Fit for 
Travel 
Government http://www.fitfortravel.nhs
.uk/advice/disease-
prevention-advice/lyme-
disease.aspx 
Lyme Disease: 
symptoms, 
causes and 
treatment 
Netdoctor Commerical, 
medical 
http://www.netdoctor.co.u
k/conditions/infections/a56
81/lyme-disease/ 
The controversy 
over the chronic 
form of Lyme 
Disease 
BBC News Media http://www.bbc.co.uk/new
s/magazine-34579423 
 
The resources were produced by a range of institutions, most commonly patient advocacy 
groups (n=4), followed by the NHS (n=2). We identified one media article, a news story 
produced by the BBC, which was over two years old. One of the pages we found is no 
 36 
longer available, Lyme Disease/BADA UK was associated with Lyme Disease UK. The 
majority of these pages presented factual information about the illness, for example, 
there were pictures showing the distinctive bullseye rash. 
In addition to providing information about acute Lyme disease, most pages also made 
reference to chronic Lyme disease. Lyme Disease Action and Net Doctor presented medical 
information, without mentioning the controversy surrounding this issue; by contrast, the 
NHS choices and Lyme Disease UK pages both explicitly referred to the controversy. We 
conclude that simple web searches, such as those likely to be conducted by the general 
public, largely yield useful information and advice for those concerned about the illness.  
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4 Discussion and conclusions 
This systematic evidence map aimed to investigate the nature and extent of empirical 
research evidence on Lyme disease in humans. This exercise identified a diverse and 
growing body of literature on Lyme disease, resulting in the inclusion of 1,098 papers. The 
scope and breadth of the identified literature on Lyme disease is broad, revealing a wide 
variety of study foci. 
 Summary of the evidence 
Generally, research in the field of Lyme disease is increasing globally, with a particularly 
predominant evidence base from the USA. However, despite many papers being identified 
from Europe, only 7 percent of European studies were from the UK. Of the 47 UK papers, 
most focused on incidence and prevalence (n=17) and diagnosis (n=15). Far fewer focused 
on symptoms (n=5), prevention (n=5), treatment (n=2), multiple aspects (n=2) or costs 
(n=1). We identified no UK papers that focused on risk factors. 
In addition to research papers, we identified 19 systematic reviews, the majority of which 
were conducted in the last three years. 
Most commonly, research populations for Lyme disease proved to be general, with most of 
the papers having no specific study population (n=868). Children were also commonly 
researched (n=133). There were few papers on high-risk populations (n=52) or other 
vulnerable populations, such as pregnant women (n=4) or older people (n=2). 
The nature of research evaluating aspects of Lyme disease is broad. Papers were grouped 
into seven domains: 1) diagnosis; 2) symptoms and co-occurring conditions; 3) incidence 
and prevalence; 4) prevention; 5) treatment; 6) risk factors; and 7) cost assessments. The 
largest body of research evidence focused on diagnosis (n=310), in particular, on diagnosis 
testing accuracy. This is followed by symptoms and co-occurring conditions (n=283), most 
noticeably on the association between Lyme disease and other conditions, such as 
Parkinson’s disease. Also, a high percentage of papers focused on incidence and 
prevalence of Lyme disease (n=189); two thirds of these focused on incidence. Far fewer 
papers focused on prevention (n=82), those included were surveys or effectiveness 
evaluations. Papers that focused on treatment are also relatively few in number (n=78) 
and predominately focused on antibiotic therapy. Research evidence on risk factors (n=46) 
was limited and focused on factors such as season and climate, human-to-human 
transmission, and contact with animals. It should be noted that studies on environmental 
risk factors were included only when outcome measures had been calculated for resultant 
disease in humans; a wider literature exists on the Lyme disease hazard to humans, based 
on field surveillance of tick-infection prevalence, but this was beyond this map’s scope. 
The few cost assessments identified (n=10) were partial economic evaluations that 
provided cost and utilisation data or cost-of-illness information. We located eighty-one 
papers that focused on more than one aspect of Lyme disease, almost half of which 
focused on both symptoms and treatment. Further, we identified systematic reviews 
(n=19), which focused on all seven domains. 
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In 2012 a priority setting exercise on Lyme disease was conducted, in the UK, by The 
James Lind Alliance (JLA), an NIHR funded non-government organisation (NGO), which 
involves patients, carers and medical professionals in identifying priorities for future 
research. The ten research priorities identified in the JLA exercise appear to reflect the 
current availability of research on different aspects of Lyme. Whilst only seven percent of 
studies in the map focused on treatment for Lyme disease (n=78) the majority of the ten 
JLA identified research priorities (n=7) focused on the efficacy and consequences of 
treatments for Lyme disease at different stages. By contrast, while almost one third of the 
studies in the map focused on diagnosis (n=310) just two of the ten JLA priorities focused 
on diagnosis (JLA, 2012). 
A variety of different research designs was described in the included papers. Research 
design is dependent upon its appropriateness for the research aims. Research that aims to 
test or evaluate the effectiveness of treatments should employ a comparative design. 
RCTs are widely accepted as being the gold standard for evaluating the effectiveness of 
interventions, however, we identified very few RCTs (n=23); these were for treatment 
(n=14) and prevention (n=9). Few qualitative research papers were identified that 
gathered patient and clinician experiences, in particular with regard to diagnosis and 
treatment. 
 Gaps in the evidence  
Whilst a high proportion of papers focused on Europe, just under five percent of included 
papers (n=47) were from the UK. 
A noticeable lack of research was identified on specific populations, such as older people, 
hikers, dog walkers and pregnant women, for all aspects of Lyme disease. Further, 
research is limited for Lyme disease manifestations other than Lyme neuroborreliosis, 
erythema migrans, Lyme arthritis and Lyme carditis. 
The reporting of the costs for interventions, such as treatment, diagnosis and vaccines, is 
limited. Only ten cost assessments were identified; 16 papers reported any level of costs. 
Lyme disease research evidence might benefit from a greater number of experimental 
studies, in the form of RCTs that evaluate the effectiveness of treatment and prevention 
interventions. It might also benefit from more evidence of patient and clinician 
experiences, in order to highlight real-world issues that impact the effectiveness of 
diagnosis, treatments and prevention. 
Few papers focused on the clinical or symptom-led diagnosis of Lyme disease (n=68), 
compared with the laboratory diagnosis of Lyme disease. 
Certain aspects of Lyme disease appear to be relatively limited. Papers focusing on the 
treatment of Lyme disease (n=78) account for less than seven percent of all the identified 
papers. Only four percent (n=46) focused on the potential risk factors associated with 
Lyme disease. 
 Strengths and limitations  
The characteristics of the search strategy and inclusion criteria of this map must be 
considered. Systematic evidence mapping provides a means to understand the landscape 
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of research that has been conducted, however, the included papers are not critically 
assessed for their methodological quality. Therefore, it is not possible for the review team 
to make judgements about the relevance or robustness of the findings reported in the 
papers. 
Despite the review team’s efforts to be inclusive, with no constraints placed on the type 
of intervention, country, or methodological design, the review did have language 
limitations. Only papers that were indexed in English-language databases, and reported in 
the English language, were included. Therefore, the extent of evidence is potentially 
greater than is reflected in this report. 
Despite identifying several hundred case reports, these are not included in this map. This 
is both a limitation of the review and of the research field, as these studies do not qualify 
as rigorous research and, therefore, do not comply with the inclusion criteria. 
It must be noted that whilst this systematic evidence map categorises papers within 
specific foci, the papers within these categories are often more complex than the group 
headings indicate. In addition, the aims and objectives of the identified papers were often 
difficult to discern and, therefore, categorise. Further, issues with the reporting of studies 
were encountered. Initially, the review team aimed to categorise papers by the nature or 
stage of Lyme disease under study, but this proved impossible due to the lack of detailed 
or explicit definitions and the variability in the terminology used. The observed lack of 
clarity in reporting may mean that relevant papers may have been missed. Researchers in 
this field should publish research that follows reporting guidelines, such as CONSORT or 
the EQUATOR Network, as a matter of course. 
The methods used in the production of this map follow the rigorous standard procedure of 
conducting systematic reviews developed at the Evidence for Policy and Practice 
Information and Co-ordinating Centre (EPPI-Centre). This systematic map benefits from 
user involvement, in the form of a scientific advisory group, as well as patient and 
professional stakeholders. 
To locate relevant research papers, the review team conducted a very comprehensive 
systematic search of electronic databases in the clinical sciences, social sciences, 
psychology, economics, and governmental and non-governmental organisations. This was 
supplemented by searching relevant websites and grey literature, checking the references 
of systematic reviews, and suggested papers from the involved stakeholders. The search 
strategy for this map was designed to be both sensitive and exhaustive, in order to gain 
insight into the range and variety of aspects of Lyme disease that have been investigated.  
However, as with any systematic review, there is a possibility that the searches may have 
missed some papers. 
To ensure consistency and quality of screening, all reviewers performed a moderation 
exercise on title and abstract screening and again for full-text screening. Due to the 
nature and diversity of the papers, identified by the search, approximately three quarters 
of the papers were double screened. Although samples of papers were screened 
independently, by two reviewers, at various stages of the screening process, there is the 
possibility that some papers may have been excluded, which should have been included 
within the map. 
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Papers included in each research topic were assigned to at least two reviewers to be 
double coded. While initial quality assurances were put into place regarding the testing of 
the coding tools for single-coder use, after coding a random sample of papers, agreement 
between reviewers, for certain research areas, was not high and, therefore, papers were 
double coded, which reduced the risk of variations in coding strategies. 
 Implications for research  
This is the first systematic evidence map of research focused on Lyme disease in humans.  
This map provides a unique resource for investigating the content of Lyme disease 
research and demonstrates the scope and diversity of research conducted in formal 
empirical studies. This map provides a valuable tool for stakeholders to understand and 
navigate the research evidence in the field, and for researchers, commissioners and 
clinicians to develop an evidence-informed approach to identify potential areas in which 
to conduct or commission further research, and to impact on policy and practice in the 
field of Lyme disease research. 
 Conclusion  
Despite identifying a large number of papers, there are many gaps in the research 
evidence base. Whilst a relatively high proportion of papers eminated from Europe 
(n=631), the 47 papers from the UK accounted for less than five percent of the total 
number of papers. In addition, we located little research that focused on specific 
populations other than children, for example, older people or pregnant women. Research 
into the diagnosis and treatment of Lyme disease might also benefit from an increase in 
papers that focus on patient and clinician experiences, as highlighted by our evidence 
reviews (Brunton et al, 2017 and Sutcliffe et al, 2017). There are relatively few papers on 
treatment and prevention; in particular more robust evaluations to test the effectiveness 
of treatments or prevention approaches (i.e. controlled design studies) might prove to be 
beneficial. Further research on the risk factors associated with Lyme disease might also 
help to further understanding in this area. Future research on interventions should report 
the costs for intervention set-up and cost per patient, as a matter of course, to inform 
commissioners and providers of healthcare services. Finally, research into Lyme disease 
would benefit from papers that focus on more clearly defined populations, interventions 
or outcomes, and are clearly reported. This would facilitate greater access to knowledge 
and help progress in research in this area. 
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5 Detailed methods 
5.1 Aims 
 User involvement 
We worked closely with the review commissioners throughout, in order to ensure that the 
review is closely aligned with their needs and emerging programme. In particular, we 
sought to identify research avenues that would support and complement the evidence 
being assembled by NICE, in 2017, to produce a guideline for Lyme disease. 
We also convened a scientific advisory group (AG) of UK and international academics and 
UK policy-makers, to obtain specialist expertise and input. The AG provided advice on an 
as-needed basis, with regard to technical issues relating to the research questions, 
concepts and definitions, as well as strategies for dissemination and impact. Lastly, we 
ran a series of consultations with patient and practitioner groups to help interpret our 
emerging findings in relation to current UK experiences. 
 Review questions 
The primary aim of this evidence map is to provide a comprehensive overview of available 
research evidence pertaining to Lyme disease in humans. To achieve this, we 
systematically identified and described the available research evidence to address the 
following question: 
 What is the nature and extent of empirical research evidence on Lyme disease in 
humans? 
A secondary, or minor, aim of the project was to understand the sources of information 
available to the public through online searches. To address this aim, we undertook a brief 
‘media scan’ to identify the most popular websites relating to Lyme disease. 
5.2 Methods 
 Searching for studies for the systematic evidence map 
Searching for studies to populate the systematic evidence map involved a broad and 
sensitive search strategy, consisting in effect of a single cluster of terms for Lyme disease. 
An example strategy is shown in Appendix 1. The following databases were searched:  
ASSIA 
British Nursing Index (BNI) 
Cochrane Central Register of Controlled Trials (CENTRAL) 
Cochrane Database of Systematic Reviews (CDSR) 
Cumulative Index for Nursing and Allied Health Literature (CINAHL) 
Database of Abstracts of Reviews of Effects (DARE) 
 42 
Embase 
Global Health 
Health Management and Information Consortium (HMIC) 
Health Technology Assessment (HTA) database 
International Bibliography of the Social Sciences (IBSS) 
MEDLINE 
PsycINFO 
PubMed 
Social Policy and Practice 
Social Science Citation Index 
Sociological Abstracts 
In addition, the following resources were searched for on-going studies, and unpublished 
or grey literature:  
ClinicalTrials.gov 
Conference Proceedings Citation Index: Science 
Conference Proceedings Citation Index: Social Science 
EU Clinical Trials Register 
ProQuest Dissertations & Theses: UK and Ireland 
PROSPERO 
WHO International Clinical Trials Registry Platform portal  
A search for guidelines on Lyme disease was carried out via the following websites: Health 
Protection Scotland, Public Health England, Public Health Wales, National Guideline 
Clearinghouse, NHS Evidence, NICE Clinical Knowledge Summaries (CKS), NICE website and 
the Trip database. 
 Including studies in the systematic evidence map 
To be included in this systematic evidence map, studies had to meet the criteria set out in 
Table 5.1 below. The table also provides details of the rationale underpinning each of the 
map inclusion criteria.  
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Table 5.1: Inclusion criteria for the systematic evidence map 
 
 Screening for inclusion in the review 
Inclusion criteria were applied to the title and abstract of each study. Full reports were 
then obtained for those references that were judged to meet our inclusion criteria, based 
on the title and abstract, or where there was insufficient information within the title and 
abstract to judge eligibility for inclusion. References that met the inclusion criteria for 
title and abstract screening were subject to a second round of screening using the same 
approach, based on the full reports of potential studies to determine a final set of papers 
for inclusion in the review.  
Criterion To be included in the 
map a study must: 
Rationale 
Date 
Be published in or 
after 2002. 
Guidance from members of the scientific advisory group 
was to focus on recent research from the last 15 years in 
order to reflect current experiences and practices 
relating to Lyme disease.  
Language 
Be published in 
English Language.  
Since the team does not have capacity to search for and 
examine evidence in all languages we will include only 
those available in English Language.  
Health 
condition 
Be about Lyme 
disease. 
Studies may focus on more than one condition but must 
include at least some focus on Lyme disease. 
Evidence 
Be an empirical 
research study OR 
systematic review. 
In addition to empirical studies, systematic reviews (i.e. 
reviews for which ≥ 2 databases were searched and 
inclusion criteria applied) will be included. Non-
empirical evidence, commentary pieces, editorials and 
non-systematic reviews were excluded.  
Population 
Be about Lyme 
disease in humans. 
Whilst studies of Lyme disease in animals and ticks may 
provide some information with implications for human 
populations, the priority is to focus in on those studies 
directly addressing Lyme disease in humans.   
Focus 
Not be a biomedical 
study focusing purely 
on markers or 
mechanisms of Lyme 
disease within blood 
samples, tissue 
samples, or cells.   
The aim of the evidence reviews is to understand 
patient and clinician experiences of Lyme, rather than 
the underpinning biomedical processes and causative 
mechanisms, in order to support DH in future policy 
development.  
For example, this criterion was used to exclude studies 
on novel diagnosis methods that were not compared 
against a reference standard as these were considered 
to be exploratory bio-mechanism studies. 
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 Data extraction and quality appraisal 
Reviewers extracted descriptive data from papers using coding tools developed specifically 
for the evidence map. An iterative and inductive approach to develop the coding tools was 
undertaken. Initially a generic tool applicable to all papers was developed. However, 
when testing this tool, it proved difficult to use, as it was not fit for purpose and in 
alignment with key aspects of studies according to their substantive topic focus. Instead, 
smaller teams took a subset of papers specific to each topic focus (e.g., diagnosis, 
prevalence, treatment, prevention, or symptoms) and developed individual coding tools to 
capture key characteristics of those studies relevant to their aim. The coding tools were 
refined, and guidance provided, for questions, where required. Coding for each paper was 
agreed by two reviewers. 
The following information was extracted from all papers:  
 Bibliographic details: e.g., publication details, and date  
 Geographical location: continent and individual country 
 Population: e.g., children, adults, high-risk groups 
Coding tools specific to each topic focused on capturing more detailed information. Where 
relevant, this included research design (e.g., aim, or research method); focus of 
investigation (e.g., type of diagnostic test, or treatment or prevention programme); 
outcomes and other contextual details. 
As this is a map, the key features of papers were descriptively analysed and written-up. 
The empirical findings from studies have been appraised for their quality and synthesised 
in separate reviews. 
 Quality assurance 
At each stage of dealing with records for the evidence map (screening titles and abstracts, 
screening full reports, and coding records), an initial sample of records was screened or 
coded by two reviewers, independently, and differences were resolved by discussion. 
Where it was not possible to get agreement, a third reviewer was consulted before a final 
decision on eligibility was made. Once an adequate level of agreement was reached (90% 
agreement rate), the remaining papers were screened and coded by a single reviewer. 
To ensure consistency and accuracy in reporting, several data cleaning steps were taken. 
Firstly, we ensured that papers were not double coded either across or within screening 
tools (e.g., with two or more codes within one screening tool, or in more than one coding 
tool, such as diagnosis and prevention). Secondly, we ensured that papers which had been 
excluded had no map codes. Thirdly, we ensured that all relevant questions in the coding 
tool were applied to each paper. Where errors appeared, groups of reviewers were asked 
to check and update their coding set and/or coding was removed. 
 Consultation with patient advocacy groups 
In October 2017, we shared the key findings of the four evidence reviews that are derived 
from this map (Brunton et al. 2017, Lorenc et al. 2017, Richardson et al. 2017 and 
Sutcliffe et al. 2017a) with eight patient stakeholder groups; the feedback received is 
reported within each of the reviews. Prior to sharing the review findings, we conducted a 
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series of face-to-face consultations with the advocacy groups, in July 2017, for our review 
on experiences of diagnosis; for further details on these consultations see Brunton et al. 
(2017). Whilst this consultation work informed the project as a whole, we did not consult 
with patient groups on the map findings specifically. 
 Media Scan  
To understand the nature of the most accessible information about Lyme disease for the 
general public on the internet we conducted a simple search, on 31 July 2017, using the 
phrase ‘Lyme disease’ on the most popular search engine (Google). We gathered together 
details of the source and content of the most popular pages, i.e. those resources listed on 
the first page of the returned search. 
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Appendices 
Appendix 1: Example search strategy 
MEDLINE (via Ovid) search strategy 
1 exp Lyme Disease/ (9589) 
2 (lyme or lymes or lyme's).ti,ab. (9797) 
3 borreliosis.ti,ab. (3230) 
4 neuroborreliosis.ti,ab. (1024) 
5 (borrelia$ adj2 arthritis).ti,ab. (38) 
6 (erythema adj2 migrans).ti,ab. (1471) 
7 1 or 2 or 3 or 4 or 5 or 6 (12593) 
8 exp Borrelia burgdorferi Group/ (6501) 
9 (borrelia adj (burgdorferi or afzelii or garinii)).ti,ab. (7347) 
10 (b adj (burgdorferi or afzelii or garinii)).ti,ab. (4289) 
11 8 or 9 or 10 (8983) 
12 7 or 11 (14245) 
13 exp animals/ not humans/ (4279323) 
14 12 not 13 (11450) 
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Appendix 2: Flow of literature through the review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records removed:  
N = 31,094 
Duplicates: N = 29,561 
Total records 
N = 52,268 
Excluded on abstract  
N = 13,621 
Exc 1: 84 
Exc 2: 2,462 
Exc 3: 4,289 
Exc 4: 4,216 
Exc 5: 2,504 
Duplicates: 66 
Total records screened 
N = 21,174 
 
Full reports included in descriptive 
map 
N = 1,098 
Criteria on which reports 
were excluded (full text) 
Exclusion 1 - Date: 
Published before 2002 
Exclusion 2 – Focus: Not 
Lyme, borrelia, 
borreliosis 
Exclusion 3 – Evidence: 
Not empirical evidence 
Exclusion 4 – Population: 
Not humans 
Exclusion 5 – Biological 
mechanisms/markers 
Exclusion 6 – Language: 
Not in English 
Exclusion 7 – 
Registrations of trials 
Exclusion 8 – Case 
Reports 
Full reports retrieved and 
screened 
N = 7,553 
Includes by research focus 
N=1098 
Diagnosis: 310 
Symptoms: 283 
Incidence/prevalence: 189 
Prevention: 82 
Treatment: 78 
Risk factors: 46 
Costs: 10 
Multiple aspects: 81  
Systematic reviews: 19 
 
Full reports not 
available:  
N = 29 
Excluded on full 
report  
N = 6,426 
Exclusion 1: 3,960 
Exclusion 2: 190 
Exclusion 3: 1,249 
Exclusion 4: 94 
Exclusion 5: 166 
Exclusion 6: 731 
Exclusion 7: 36 
 
Criteria on which reports 
were excluded (abstract) 
Exclusion 1 - Date: 
Published before 1980 
Exclusion 2 – Focus: Not 
Lyme, borrelia, 
borreliosis 
Exclusion 3 – Evidence: 
Not empirical evidence 
Exclusion 4 – Population: 
Not humans 
Exclusion 5 – Biological 
mechanism/markers 
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Appendix 3: Number of papers by country* 
* numbers are not mutually exclusive
Africa (n=1) Europe (continued) 
Egypt 1 Luxemburg 1 
Asia (n=40) Macedonia 1 
China 14 Montenegro 2 
Turkey 14 Netherlands 31 
Iran 1 Norway 30 
Japan 3 Poland 61 
Korea 2 Portugal 2 
India 2 Romania 11 
Malaysia 1 Russia 17 
Mongolia 1 Serbia 5 
Taiwan 2 Slovakia 16 
Australasia (n=4) Slovenia 47 
Australia 3 Spain 9 
New Zealand 1 Sweden 52 
Europe (n=631) Switzerland 14 
Austria 32 Turkey 14 
Belarus 3 United Kingdom 47 
Belgium 13 Ukraine 2 
Bosnia and Herzegovina 1 Multi-country (SR + EU) 3 
Bulgaria 7 Not reported 4 
Croatia 5 North America  (n=404) 
Czech Republic 40 Canada 26 
Denmark 11 Mexico 2 
Estonia 2 USA 374 
Finland 22 Cuba 1 
France 28 No country  reported 1 
Germany 84 South America (n=8) 
Greece 1 Brazil 7 
Hungary 8 Venezuela 1 
Ireland 4 No geographical country limit (n=16) 
Italy 28  
Latvia 3 
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